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Abstract for Critical Review of Literature
Background: With the increase of IV drug use, Hepatitis C viral (HCV) infections have
increased considerably among the homeless population. The introduction of direct-acting
antiviral (DAA) medications has made treating marginalized populations much easier. However,
getting homeless patients and people who inject drugs (PWID) linked to care remains a challenge
worldwide. More research is needed to ensure that all persons with HCV are able to access
treatment regardless of social or economic status.
Theoretical Framework: Nola Pender’s Health Promotion Model (HPM) guided this systematic
review of literature.
Methods: Eighteen articles were analyzed for this review of literature. The majority of the
studies used for this review were published within the past 5 years. All the studies selected
included homeless participants, and one or more of the following; HCV education, linkage to
care related to HCV testing and treatment, and SVR12 rates. The articles were assessed using
John Hopkins Evidence Based Practice Model (Dang & Dearholt, 2018) and findings were
organized using Garrard’s Matrix Method (Garrard, 2017).
Purpose: The purpose of this critical review of research is to identify models of care for treating
HCV among the homeless. This review was done to support research regarding linkage to care
for homeless patients with HCV currently being conducted by Hennepin County’s Healthcare for
the Homeless and Hennepin Healthcare Gastroenterology and Liver Clinic located in
Minneapolis, Minnesota.
Results: Following the framework of HPM, the research identifies that homelessness comes with
significant barriers to receiving HCV education, testing, and treatment interrupting the goal of
health promotion. Additionally, patients who are homeless recognize the benefits of being treated
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and perceive a cure as erasing the stigma associated with HCV (Williams, et al., 2019).
However, many homeless patients are often lost to follow up when referred to off-site providers
for treatment. The literature revealed that HCV healthcare models most effective in treating the
homeless include; HCV education with a process for providing the HCV care continuum at
homeless shelters, community clinics, or other places where the homeless frequent; and an
enhanced level of nursing support to control barriers to care.
Conclusion: This review regarding HCV healthcare models indicate that navigating homeless
patients through the HCV care continuum is challenging and requires further research. However,
the review of literature identifies essential components of HCV healthcare models, as well as
factors to consider when treating this population. First, PWID and are homeless should be
considered for treatment to reduce disease burden. Secondly, the shift from specialty care to a
broader treatment team for patients without advanced liver disease has allowed HCV care to
occur in a location convenient for the homeless to access. Lastly, addressing the social and
interpersonal barriers through an enhanced support model for HCV care has shown to increase
medication initiation, adherence, completion, and SVR12 testing.
Implications for Research and Practice: Gaps in HCV education, testing, and treatment among
the homeless provides continued opportunities for nurses to educate both communities and
students in an effort to decrease disease burden. Nursing research should focus on understanding
what type of enhanced support is most effective in getting homeless patients through the HCV
care continuum.
Keywords: Hepatitis C (HCV), homelessness, HCV healthcare models, HCV education, public
health nursing.
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Chapter One: Introduction
Homeless adults with associated intravenous drug use (IVDU) are disproportionately
affected by Hepatitis C infection (HCV), compromising their overall health (Fuster & Gelberg,
2019). The introduction of highly effective and safe direct-acting antivirals (DAAs) for the
treatment of HCV has allowed previously labeled “difficult to treat” populations to be readily
treated (Yek, et al., 2017). These new improved short duration treatments have a 95% cure rate,
encouraging the ramp-up of treatment for underserved populations in an effort to decrease the
burden of HCV infection (Grebely, Hajarizadeh, Laarus, Bruneau, & Treloar, 2019). Research
regarding obstacles to providing treatment and increasing awareness for HCV in this vulnerable
population has provided a foundation for helping clinicians in community settings design
pathways to screening, linkage to care and treatment (Grebely et al., 2019). However, homeless
patients continue to be the hardest population to connect to treatment, despite being one of the
populations most affected by this disease (Dever et al., 2017).
Statement of Purpose
This Capstone project is written to provide a review of research to inform an HCV study
being done in coordination with the Hennepin County’s Healthcare for the Homeless and
Gastroenterology-Liver Clinic at Hennepin Healthcare. The goals of this critical review of the
literature are to assess knowledge and attitudes about HCV, identify barriers to testing, and
understand if treatment uptake improves through integrative services such HCV education, onsite treatment, and adherence support. The larger ongoing study will look at whether a model
providing education and testing for HCV in homeless shelters with linkage to treatment in an onsite clinic is an effective way to decrease disease burden within this population. The goal of this
critical review is to determine what healthcare model is most effective in providing access to
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comprehensive HCV treatment with a sustained viral response at 12 weeks post-treatment
(SVR12) for the homeless population.
Need for Critical Review
Hepatitis C infection is only spread by blood-to-blood contact; it is more prevalent than
HIV and is one of the most common causes of cirrhosis and liver cancer (National Institute of
Diabetes, Digestive and Kidney Disease [NIH], n.d.). The Centers for Disease Control and
Prevention (CDC) (n.d.) attributes the rising rate of reported Hepatitis C viral infection from
2010 through 2016 to the rising rates of intravenous drug use (IVDU). Homeless adults have a
high rate of IVDU and non-injected drug use (NIDU) which makes them a high-risk group for
acquiring HCV (Beiser, Leon, & Gaeta, 2017). Hakobyan et al., (2018) meta-analysis of 15
epidemiological studies showed a 28% prevalence rate of HCV in the homeless, which has
remained unchanged since 2012. In addition, treatment uptake (initiation of medications) and
adherence is low among the homeless due to loss of follow up (Coyle et al., 2019). Within the
last eight years, new oral treatments, known as direct-acting antivirals (DAA), have made
achieving a cure much more attainable than the previous intravenous treatments (Hepatitis
Central, n.d.). DAA oral medications have been shown to cure HCV in as little as eight to twelve
weeks with daily oral treatment and minimal side-effects (Hakobyan et al., 2018). However,
many homeless individuals are not connected to the healthcare system and have never been
tested for HCV (Tyler et al., 2014). Infection is being spread to others because those infected
receive little education on HCV and are not aware they have it, nor the debilitating symptoms
that can occur with chronic infection (Tyler et al., 2014). HCV, as well as homelessness, is a
world-wide issue with an estimated 71 million chronic infections globally (World Health
Organization [WHO], 2019a). Therefore, the WHO has implemented a global initiative of
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eliminating HCV as a major global health threat by reducing new HCV infections by 90% and
reducing HCV deaths by 65% between now and the year 2030 (World Health Organization
[WHO], 2019b).
Research has shown how homelessness is an independent risk factor for HCV infection
due to the high rates of IVDU among the homeless (Strehlow et al., 2012). This association has
led to several research studies looking at how to improve HCV knowledge and increase
treatment among homeless adults (Grebely et al., 2019). Some homeless shelters in large urban
areas have partnered with public health departments to staff advanced practice providers, nurses
and pharmacists within the shelters to help clients with medication adherence and access to
healthcare. Hennepin County’s Healthcare for the Homeless program is one example of this type
of partnership in Minneapolis, Minnesota (National Healthcare for the Homeless Council,
n.d.). With an estimated 5,500 homeless people in Hennepin County, it is important to
understand what methods can be used to increase HCV awareness, testing, and treatment to
decrease rates of HCV transmission (National Healthcare for the Homeless Council, n.d.). The
research currently trending shows community outreach through onsite clinics at homeless
shelters as a developing approach to ensuring a pathway to better healthcare in this high-risk
group. This trend is seen specifically in HCV research being done in large cities around the
world such as Boston, Los Angeles, Philadelphia, Sidney, Australia and Tehran, Iran (Alavi et
al., 2019; Coyle et al., 2015; Coyle et al., 2019; Bajis, 2019; Beiser, Smith, Ingemi, Mulligan, &
Baggett, 2019; Fuster & Gelberg, 2019). The goal of this research study is to show that a model
supporting HCV education and point of care testing within two Minneapolis homeless shelter
clinics can effectively link HCV infected homeless adults to treatment while providing a model
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for continued care for other health concerns related to homelessness. The following
abbreviations as shown in Table 1 will be used throughout the rest of this review.
Table 1
Common Abbreviations Used in HCV Research
Abbreviation

Meaning

CDC

Center for Disease Control and Prevention

DAA

Direct-acting antiviral

EOT

End of treatment

HCV

Hepatitis C virus

IV drugs

Drugs that are inserted intravenously

IVDU

Intravenous drug use

NSP

Needle and syringe program

OAT

Opioid agonist therapy

OUD/SUD

Opioid use disorder/substance use disorder

POC

Point of care

PWID

People who inject drugs

RNA

Ribonucleic acid

SMA

Shared medical appointment

SVR12

Sustained viral response 12 weeks post-treatment

VA

Veteran’s Administration

WHO

World Health Organization

14

Significance to Nursing
Nurses work in a variety of healthcare settings and are often in the role of screening and
educating patients. Patients with Hepatitis C infection are not always clinically ill (CDC, n.d.).
Therefore, initiating screening guidelines to determine risk factors is the best way to determine if
a patient should be tested for this infection (Pilger & Costanzo, 2018). Before the Centers for
Disease Control and Prevention (CDC) published the recommended screening guidelines for
Hepatitis C in 2012, this infection was predominantly viewed as a health issue for PWIDs
(people who inject drugs) (Pilger & Costanzo, 2018). This led to a misconception that all HCV
infected patients had used IV drugs (as cited in Pilger & Costanzo, 2018). Although IVDU
increases the risk for acquiring HCV, it is not the only risk factor. Receiving blood transfusions
or organ transplants before 1992 increased the risk of HCV exposure along with many other
factors (Pilger & Costanzo, 2018). Currently, the CDC recommends screening for HCV for:
Anyone who was born between 1945-1965, history of IV drug use, those who received
blood or organ transplant prior to 1992 or blood clotting products before 1987, anyone
born to a mother with HCV, a known exposure to HCV, and anyone with elevated
alanine transaminase. (as cited in Pilger & Costanzo, 2018, p. 71)
Understanding and identifying patients who could be at risk for Hepatitis C infection are
important elements in providing better health outcomes for our patients, which will inevitably
lead to better overall public health. Knowing all the risk factors for HCV allows nurses to
educate patients about the infection, eliminate associated stigmas, and recommend screening.
There are two blood tests used to identify exposure to HCV. The anti-HCV test is used
for screening and identifies antibodies, but this does not confirm infection (Pilger & Costanzo,
2018). Positive anti-HCV tests should be followed up by HCV ribonucleic acid (RNA) testing
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that confirms infection (Pilger & Costanzo, 2018). Nurses should be aware that antibodies for
HCV show past exposure, but about 25% of people clear infections on their own (Pilger &
Costanzo, 2018). HCV RNA is also used to confirm a cure. According to the American
Association for the Study of Liver Diseases (AASLD) (2017, Table 2), “Quantitative HCV viral
load testing is recommended 12 or more weeks after completion of therapy to document a
sustained viral response (SVR) (cure).” Some Hepatologists will test response at the end of
treatment since testing for a negative HCV RNA provides an indication that the patient has
adhered to treatment (J. Powell, personal communication September 4, 2019). However, because
relapse can occur after treatment, a second blood test should always be done 12 weeks after
treatment completion to confirm a sustained viral response (SVR12) (AASLD, 2017). Studies
being done with treatment compliant participants show less than 10% of those treated with DAA
agents do not achieve SVR12 (Yek et al., 2017). When patients test positive for HCV, it is
important for nurses to be able to explain the treatment as well as the importance of the blood
tests to ensure a cure is achieved. Achieving SVR12 is very important because eradicating the
HCV infection will decrease the risks of developing cirrhosis and hepatocellular cancer (HCC),
significantly improving the patient’s quality of life (Yek et al., 2017).
Before 2012, HCV treatment involved an immunomodulating therapy called Interferon
and was combined with oral Ribavirin (Yek, et al., 2017). The treatment lasted for up to 48
months, had many intolerable physical, neurological and psychiatric side effects, and provided
only a 50% chance of obtaining an SVR (Yek et al, 2017). Incidentally, there was only a 20%
chance of achieving SVR12 if the patient was African American (J. Powell, personal
communication, September 4, 2019). Through personal correspondence with patients formerly
treated with Interferon therapy and being re-treated with the DAA agents, I have found that

16

patients are mostly concerned about experiencing side effects similar to those of Interferon.
Because HCV treatment has become much more accessible with new DAA oral treatments, it is
important for nurses to explain the treatment to patients who have acquired a new HCV infection
or did not achieve SVR12 with prior therapy, so they understand how much shorter, tolerable,
and effective treatment has become.
Theoretical Framework
The ultimate goal of Hepatitis C treatment is to cure HCV infection and improve one’s
overall health and eliminate the spread of this infection to others. The literature review regarding
the need to increase awareness of Hepatitis C infection among the homeless to promote testing
and treatment is well supported by Nola Pender’s Health Promotion Model (HPM). This theory
is based on the two human behavior theories, Fishbein & Ajzen’s Expectancy Theory and
Bandura’s Social-Cognitive Theory (McCullagh, 2016). Expectancy Theory suggests that
achieving a goal is based on its perceived value and benefits while Social-Cognitive Theory
explores the need for self-efficacy to engage in behavioral change (McCullagh, 2016). The HPM
provides a framework of behavioral cognitions that the nurse must consider, such as the patient’s
lifestyle and commitment to discontinue risky behaviors while being treated and after treatment.
The nurse can evaluate for situational and personal influences that might prohibit behavioral
changes needed for better health outcomes (McEwen, 2014). Patients living in homeless shelters
have several barriers that prevent them from committing to healthy behaviors. Being uneducated
about HCV infection, combined with homelessness, lack of insurance, chemical addictions,
mental illness, competing priorities, social influences, and transportation issues all affect the
client’s ability to commit to a plan for HCV testing and treatment. Pender’s revised 2006 model
acknowledges that past experiences, along with personal issues, are major motivating factors in
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committing to a health promotion plan and suggests that nurses can direct the patient towards
interventions that are specific to the client’s needs (McEwen, 2014). By implementing treatment
readiness visits with homeless clients interested in starting medications, the nurse is able to
screen for specific barriers that could prevent a patient from being compliant. During these visits,
the nurse can have a conversation with the patient to understand their own unique challenges to
completing treatment. My experience working with HCV patients has shown that clinic visits
with a nurse prior to starting treatment have helped to expose and solve issues that could be
problematic in treatment uptake and adherence.
Additionally, Pender’s model is intended to increase the level of wellness for an
individual, group or community (McCullagh, 2016). Therefore, HPM is a model that can be
applied to both the wellness and education of Hepatitis C at the community level in homeless
shelters and help evaluate treatment readiness for each individual patient. Applying Pender’s
model to homeless patients in promoting awareness and education regarding HCV risk factors
can assist in implementing a comprehensive program that leads to increased HCV testing and
instills self-efficacy among clients to make informed decisions regarding treatment and avoid reinfection.
Summary
Although achieving a cure is easier with DAA therapies, getting marginalized
populations through treatment remains a challenge as noted by the research done by Yek et al.
(2017). For the homeless, there are many barriers preventing effective treatment such as
substance abuse, stable housing, keeping medications secure, lack of insurance, and
transportation issues. Nurses can assist in educating vulnerable populations about HCV so they
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can make informed decisions about testing and treatment and help them find solutions to
treatment barriers.
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Chapter Two: Methods
There has been an increasing interest among the medical and public health communities
to test and treat the homeless population for Hepatitis C with the development of the new
tolerable and effective DAA agents to help meet the World Health Organization’s goal of
eliminating HCV by 2030 (Grebely et al., 2019). However, Masson et al. (2013) found that
individuals reporting homelessness were least likely to follow through with HCV evaluation.
Additionally, even when the homeless ae linked to care, completing treatment and obtaining
SVR12 rates remains difficult in many homeless populations, especially those who do not
frequent shelters (Harney et al., 2019). In an attempt to identify healthcare models that are
successfully treating homeless adults with HCV, a comprehensive search for articles examining
this issue was completed. This chapter discusses how the search was defined and the types of
research studies reviewed to answer the clinical question.
Search Strategies
A literature search was conducted using the Cumulative Index to Nursing and Allied
Health Literature (CINAHL), Scopus, Science Direct, Cochrane Database of Systematic
Reviews, and PubMed to address the clinical question: What type of healthcare model is most
effective in providing access to comprehensive HCV treatment with SVR12 for the
homeless? Terms searched included: homeless, Hepatitis C, Hepatitis infection, nurse, linkage to
care, health promotion, education, direct-acting antiviral (DAA) medication, and SVR12. Due to
the high prevalence of Hepatitis C infection from IVDU within the homeless and underserved
populations, research regarding this issue was very accessible. A search using “Hepatitis C and
homeless” together yielded 42 results on Scopus, 98 results on CINAHL, and 254 results on
PubMed. Therefore, the additional terms “education” and “linkage to care” was combined with
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“Hepatitis C and homeless” when entered into the search engines to narrow the findings to
relevant research regarding the practice question. This yielded 85 results. To further refine the
search, a limit of 8 years (2010-present) was applied to CINAHL and Scopus and a limit of 5
years (2013- present) was applied to PubMed; this yielded 58 total studies. Additionally, another
search using ScienceDirect was done combining the terms “Homeless” “Hepatitis C” and
“SVR12” or “Nursing” with a parameter of years 2015 -2019. This search resulted in 11 very
recently published studies. These parameters kept the information relevant to the new era of
treating HCV infections with DAA oral medications in homeless populations.
Inclusion and Exclusion Criteria
The majority of the studies selected were published within the last five years, providing
the most current research related to the clinical question. In addition, any of the studies that
addressed the issue of HCV treatment would be using the more tolerable DAA oral treatments.
The studies were excluded if patients were treated with outdated HCV therapies, such as
Interferon combined with ribavirin, with the exception of one study that was kept for the highquality research it provided regarding factors related to homelessness and healthcare follow
through. The inclusion criteria for the studies selected required that the study population include
homeless participants, and one or more of the following; HCV education, linkage to care related
to HCV testing and treatment, and SVR12 rates. This further reduced the number of relevant
studies to 18 (see Table 2) that have been reviewed to answer the posed clinical question.
Criteria for Evaluating Research Studies
The evidence presented in the articles was appraised by both the level and quality, using
tools from the Johns Hopkins Nursing Evidence-Based Practice: Model and Guidelines (Dang &
Dearholt, 2018). The Johns Hopkins Research and Non-Research Evidence Appraisal Tools
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assisted in organizing the articles by research or non-research, then further categorizing them by
the type of research; Experimental (Level 1), Quasi-experimental (Level 2), Non-experimental
and qualitative (Level 3), Practice guidelines (Level 4), or Expert opinion (Level 5) (Dang &
Dearholt, 2018). Additionally, each article was independently assessed for high quality, good
quality, and low quality/major flaws using the ratings provided in the John Hopkins Quality
Guide (Dang & Dearholt, 2018, p. 278-279). The articles and findings are organized using
Garrard’s matrix model (Garrard, 2017) (see Appendix 1).
Number and Types of Studies Selected for Review
Level I articles are randomized control trials. Level II articles are quasi-experimental
studies. Level III studies consisted of 12 non-experimental studies and one systematic review.
There were no Level IV or V studies used in this review. Table 2 shows the breakdown of each
level and associated quality for the 18 studies.
Table 2
Levels and Quality of Research
Quality
High

Good

Low

I

2

1

0

II

1

1

0

III

6

7

0

Level

22

Summary
This chapter highlights the process used to select the articles in this critical review of
nursing literature. It explains how the articles were obtained using a variety of scholarly research
engines, how the literature was categorized using the John Hopkins Evidence-Based Research
and Appraisal Tool (Dang & Dearholt, 2018) and the inclusion and exclusion criteria used to
select the 18 articles reviewed for the matrices.
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Chapter Three: Literature Review and Analysis
The selected articles are alphabetically presented using Garrard’s Matrix Model (2017)
(see Appendix 1). The matrix model includes the article title, purpose for the research, sampling
and setting, design method, conclusion, strengths, limitations, results and the level and quality of
evidence as appraised the John Hopkins Level of Evidence and Appraisal Tool (Dang &
Dearholt, 2018). The Level I studies support the importance of providing HCV education as a
pathway to treatment. There are two quasi-experimental, Level II, studies that both compare two
different healthcare models and their impact on HCV treatment outcomes among homeless
populations. The 13 Level III studies include a variety of non-experimental studies and one
systematic review. These studies looked specifically at healthcare models being used to test and
treat HCV infection among underserved populations, including the homeless. This chapter will
discuss the synthesis of the major findings regarding HCV healthcare models for the homeless,
as well as the limitations and strengths of the research reviewed.
Synthesis of Major Findings
The United States is not the only country experiencing a high HCV disease burden
among its homeless population. Global rates of HCV infection among the homeless are estimated
to be between 4 to 36% (Grebely et al., 2019). Four of the 18 articles reviewed include
healthcare models for treating HCV infection among homeless populations outside the United
States. These studies were conducted in Melbourne and Sidney Australia; Tehran, Iran, and
Dublin, Ireland. The ideal healthcare model for targeting and treating the HCV infected homeless
populations with DAA medications continues to be explored through ongoing global research.
The research reviewed reveals themes that appear within the HCV healthcare models in
an attempt to get patients through the HCV care continuum. The most prominent themes
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observed from the healthcare models reviewed are: Providing education increases awareness,
knowledge gain, and HCV testing; POC testing and onsite treatment have better outcomes than
POC testing and linkage to care off-site; the level of support provided can impact HCV treatment
outcomes; treating homeless clients who currently inject drugs has the potential to decrease
disease burden; and homelessness is the most significant barrier to completing the HCV care
continuum.
The care continuum is a series of steps that must happen to successfully treat the HCV
patient. The healthcare continuum for viral hepatitis according to the WHO consists of
prevention, screening with linkage to care, and treatments (as cited in Heffernan et al., 2017) (see
Figure 1). Figure 1 explains the HCV care continuum and illustrates how the number of
homeless clients actively engaged in HCV care decreases with each stage.
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Figure 1. HCV care continuum. Adapted from “Aiming at the Global Elimination of Viral
Hepatitis: Challenges Along the Care Continuum,” by A. Hefferman, E. Barber, N. A. Cook, A.
Gomaa, Y. Harley, C. R. Jones, … S. D. Taylor-Robinson, 2018, Open Forum Infectious
Diseases, 5(1), p. 2. Copyright 2017 by Oxford University Press.
HCV Education
Research regarding HCV has found that providing education increases awareness,
knowledge gain, and testing. Grebely et al. (2019) systematic review of 21 original research
studies, two systematic reviews, and three expert opinions acknowledge that a lack of HCV
knowledge prevents testing and treatment. Three out of the 18 studies for this review of
literature looked specifically at education techniques and their effectiveness in educating
homeless adults about HCV. Additionally, another eight studies reviewed indicate that a pre-test,
post-test, initial education or counseling was provided to patients as part of the HCV treatment
model. Level III research with high quality done by Norton et al. (2014) exemplifies why
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providing HCV education for the homeless should be included in healthcare treatment models.
Norton et al. (2014) assessed the knowledge gain of 140 participants from two homeless shelters,
two drug and rehabilitation centers, and a women’s drop-in shelter after participants were
provided a 15-minute verbal discussion regarding HCV prevention, testing, clinical importance,
and treatment. The research outcomes showed baseline HCV knowledge was low, and
participants had many misconceptions regarding how HCV is spread. Sixty-five percent of the
participants thought there was no cure for HCV. Significant knowledge gains (p < 0.05) in the
categories of how the infection is spread, what makes the infection worse and understanding
treatment were achieved with a significance of p < 0.0074 - 0.0001 (Norton et al., 2014).
Additionally, Norton et al. (2014) findings showed increasing HCV knowledge among homeless
adults led to an increase in HCV testing although treatment was not offered in correlation with
the study. Alavi et al. (2019) showed that after education was provided to their participants, 97%
of HCV infected homeless participants surveyed (n=22) were willing to be treated after receiving
the education and 87% initiated HCV treatment.
Masson et al. (2013) research consisted of a randomized control trial (RCT) of 489
participants from two methadone treatment clinics located in New York and San Francisco with
40% reporting homelessness in the past six months. Their research concluded that the
intervention group receiving motivational interviewing (MI) enhanced counseling regarding
Hepatitis was more likely to complete Hepatitis A (HAV) and B (HAB) vaccines offered on-site,
have greater reductions in alcohol use, and receive HCV evaluations sooner when compared to
the group who received the standard education with off-site referral for vaccines and HCV
evaluations. However, participants reporting homelessness in the past six months were less likely
to attend the initial HCV evaluation (Masson et al., 2013). Larios et al. (2104) RCT also looked
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at MI and its effectiveness in HCV knowledge gain and retention among 440 participants at the
same two sites studied by Masson et al. (2013). It was concluded that MI enhanced education
provided by MI trained staff did not provide an additional gain in knowledge when compared to
a nurse-led standard education intervention (Larios et al., 2014). Lastly, a RCT study by
Nyamathi et al. (2013) assessed the impact of a nurse led cognitive health promotion program
(HPP) versus an arts therapy program for improving HIV and hepatitis knowledge and overall
mental health for 156 homeless youth and young adults, ages 15-25 (median age 21.1) currently
using drugs and frequenting a homeless drop-in shelter. This study showed just a bit more
improvement of HIV (p < .001), HBV and HCV (p < .001) knowledge and psychological
wellbeing with those who participated in the nurse led HPP versus the arts therapy program.
Although some of the studies also include education on HIV and HBV infections,
conclusions drawn from this research indicate the importance of education regarding HCV
transmission, testing, and treatment in improving knowledge about HCV and increasing interest
in HCV testing regardless of the teaching style used. None of these studies followed participants
through HCV treatment to understand the effect of education on treatment adherence. The
research reviewed indicates that education is only a piece of this very complicated healthcare
issue and cannot solely drive the homeless towards testing and treatment. This research suggests
that in addition to homeless shelters, community-based primary care clinics and opioid treatment
centers are appropriate places to educate at-risk populations about HCV (Norton, et al., 2014;
Masson et al., 2013). Incorporating education, understanding treatment barriers and providing
on-site testing are initial steps that can help control HCV disease burden (Norton et al., 2014).
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POC Testing and Linkage to Care
Ten of the 18 studies reviewed are Level III non-experimental studies that presented
research using models for treating homeless adults with HCV through shelters, community
clinics, SUD clinics, and referrals to off-site specialists. The research indicates that POC testing
and onsite treatment show better outcomes than POC testing and linkage to care off-site (Coyle
et al., 2019). Grebely et al. (2019) systematic review showed that POC HCV testing and
treatment increases overall uptake of HCV treatment. Coyle et al. (2015) study recognized that
having on-site HCV RNA testing and treatment teams yielded higher rates of completing referral
appointments because all services were offered in the same setting. This study did not follow
participants through treatment and SVR12.
Sena et al. (2016) demonstrated that linkage to HCV care was improved among
underserved populations when the Department of Health sites already testing for HIV, HCV and
STD infections in Durham Country, NC began treating HCV infections. In this study, 241 out of
2,004 tested for HCV were positive with the highest percentage of chronic HCV infection among
the homeless (Sena et al., 2016). Many of the participants were not attending their off-site clinic
visits for evaluation and treatment. Therefore, the center began treating at the POC test sites.
Consequently, 81.7 % of participants received HCV results and counseling and 91.8% of patients
attended their first appointment (Sena et al., 2016).
Coyle et al. (2019) compared HCV treatment and cure rates between four federally
funded HCV test only sites and one test and treatment center in Philadelphia, PA (n=885). The
results found similar results to Sena et al. (2016) regarding high rates of breaks in treatment with
referrals to off-site treatment centers and higher prevalence rates of HCV infection seen in sites
serving the homeless. Additionally, Coyle et al. (2019) followed patients through treatment and
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found that their test and treat centers had SVR12 achievement rates that were six times that of
test only sites. Notably, the homeless participants were treated through the test only site and
SVR12 rates from those sites were only 2.5% (Coyle et al., 2019).
Lastly, qualitative research with high quality by Lambert et al. (2019) regarding HCV
burden among the homeless in Dublin, Ireland noted that only 46 out of 199 Hepatitis C antibody
positive participants actually received a referral to hospital-based care for confirmation testing
and treatment, of which 21 attended two or more appointments. Consequently, only two
treatment completions were seen (Lambert et al., 2019). Lambert et al. (2019) did note that their
research was done during a homeless crisis which affected the amount of support provided for
participants in the referral process and providing on-site treatment for Hepatitis C was not an
option in Ireland at the time of the study.
Overall, recommendations from the studies reviewed in this section suggest expanding
on-site HCV test and treat centers to avoid a loss to follow up by referring to off-site
providers. However, more research is needed to provide information regarding the hurdles to onsite treatment, as seen in Ireland (Lambert et al., 2019).
The Impact of HCV Treatment Support
The level of support given can impact HCV treatment outcomes by controlling barriers to
treatment. As discussed in chapter one, competing priorities and transportation issues can
considerably affect the homeless client’s ability to commit to a plan for HCV testing and
treatment. Grebely et al. (2019) concluded from their systematic review regarding Hepatitis C
infection among PWID that barriers to treatment must be understood to provide equitable HCV
healthcare.
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The Coyle et al. (2015) study regarding the initiation of an HCV care coordination model
between five federally funded qualified health centers (FQHC) serving the homeless in
Philadelphia, Pennsylvania used reflex testing to immediately test persons with positive HCV
antibodies (n=4,514) for HCV RNA. Patients with HCV RNA were connected to a care
coordinator for treatment on-site if available or through referrals to an off-site treatment clinic.
Coyle et al. (2015) research showed that implementing a care coordinator to provide intensive
services, such as rescheduling missed appointments and addressing barriers to care, was
instrumental in increasing the number of patients receiving their results by almost 70%, referrals
for treatment by 49.2%, and the number of patients being seen by a specialist by 29.6%.
Hodges, Reyes, Campbell, Klein, and Wurcel’s (2019) quasi-experimental research
looked at SVR12 results between patients from a community health center serving high numbers
of homeless patients who selected a shared medical appointment (SMA) with their peers during
HCV treatment versus those who choose an independent appointment. The SMA model provided
peer support which helped to decrease HCV stigma and encourage healing (Hodges et al., 2019).
Although both groups had high rates of treatment completion, participants in the SMA model
had a higher rate of SVR12 than in the independent appointment model, 91% to 69%
respectively (Hodges et al., 2019). Additionally, this model treated HCV patients where their
substance use disorders (SUD) were being managed which may have positively influenced
treatment adherence by participants (Hodges et al., 2019).
Another study by Beiser et al. (2019) assessed the HCV care continuum from treatment
initiation to SVR12 for 300 predominantly nonwhite males who were either homeless (n=84) or
living in transitional treatment facilities Boston, Massachusetts. Beiser et al. (2019) provided
adherence support through a nursing care coordination model ranging from monthly, weekly, and
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daily reminder calls to medication storage; and weekly pill box fills with follow up pathology at
four weeks, EOT, and SVR 12. The study yielded impressive results with 255 achieving SVR 12
out of the 300 who initiated treatment (Beiser et al., 2019). Beiser et al. (2019) concluded that
designated nursing support positively impacts medication adherence and cure rates for the
homeless.
Read et al. (2017) quasi-experimental study looked at outcomes of DAA treatment using
two different adherence models, enhanced and standard, at a primary health care setting in
Sydney, Australia. Thirty percent of the patients in the study had been homeless in the past year
and 44% reported injecting drugs at least weekly (Read et al., 2017). Standard support allowed
the patient to pick up and administer their medication independently with a call from a nurse
coordinator ensuring they initiated treatment and followed through with the standard lab work at
four weeks, EOT, and SVR12 (Read et al., 2017). Level of support was decided between the
nurse and patient and based on “patient’s drug use, social stability, ability to store medication
safely, and success in prior medication adherence” (Read et al., 2017, p. 210). Twenty-five out of
72 participants elected enhanced support, where a nurse provided weekly phone calls to ensure
medication adherence, observed daily, weekly or monthly administration of medications, and
partnered with prisons, psychiatric units or hospital units to deliver medications to patients (Read
et al., 2017). Overall, 19 (n=25) participants achieved SVR 12 with enhanced support (Read et
al., 2017). Fifty-nine participants achieved SVR12 overall from both groups, although 47 %
attended SVR12 testing over four weeks late (Read et al., 2017). These results indicate that HCV
care support is essential for achieving post-treatment follow up for marginalized populations and
enhanced support may be critical in getting patients through treatment who would otherwise be
lost to follow up (Read et al., 2017).

32

The studies reviewed in this section indicate that providing HCV care coordination for
the homeless appears to increase treatment adherence, completion and SVR12 testing by
eliminating barriers that cause loss to follow up. These studies indicate that high levels of
support can help control treatment barriers and improve the completion of the HCV care
continuum among the homeless. However, the studies reviewed suggest that more research is
needed in all areas of HCV treatment models for the homeless to truly understand what part of
the support model is most influential in completing the care continuum.
Treating PWID to Reduce Disease Burden
As discussed earlier, research has shown how homelessness is an independent risk factor
for HCV infection due to the high prevalence of IVDU (Strehlow et al., 2012). Yet, the research
indicates that treating the homeless who continue to use drugs has the potential to decrease
disease burden although reinfection can occur. Several studies in this review show that people
using IV drugs are highly motivated to cure their HCV infection and complete treatment and that
substance abuse is not a barrier to treatment (Alavi et al., 2019; Bajis et al., 2019; Beiser et al.,
2019; Read et al., 2017; Williams et al., 2019). Specifically, Williams et al. (2019) qualitative
study looked at themes that motivated PWID to complete DAA treatment within a life project
analysis. The study was done between two groups in Portland, Oregon receiving HCV treatment
from a homeless clinic and either receiving OAT or partaking in a needle and syringe program
(NSP) (Williams et al., 2019). Both groups identified removing the social stigma, improved selfworth, and the ability to care for themselves as the result of completing HCV treatment
(Williams et al., 2019). In the Beiser et al. (2019) study there was no significance (p < 0.05)
between opioid use disorder (OUD) and missing doses of medication (p < 0.375).
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The research also indicates that SVR12 can be achieved among PWID. Read et al.
(2017) showed high rates of SVR12 achievement among a group of participants with 44%
reporting weekly IV drug use. Grebely et al. (2019) systematic review also found that recent
injection drug use did not affect SVR12. Although Beiser et al. (2019) identified a CI of 95% for
both treated and untreated opioid use disorder (OUD) as having lower odds of achieving SVR12,
high percentages of SVR12 in both groups (82.8 % untreated OUD and 87.1% treated OUD
obtained SVR) was achieved. Alavi et al. (2019) identified in their research that 100% of
participants who had injected drugs within the last 12 months (n=13) initiated HCV treatment.
Consequently, 62% (n=8) completed treatment and achieved SVR12, four were lost to follow up
and one participant relapsed.
There was only one Level III study with good quality by Dever et al. (2017) regarding
HCV engagement among Veterans (reporting homelessness within the past five years) that
showed with significance (p <0.05) that alcohol and drug use within the prior year of being
offered HCV treatment affected one’s ability to engage in care (p=0.045).
Study recommendations suggest that HCV treatment models should be targeted to
support PWID in an attempt to decrease disease burden worldwide. However, more research will
need to be done regarding reinfection rates to understand if disease burden is being positively
affected by treating people who continue to inject drugs (Grebely, et al., 2019).
Impact of Homelessness on HCV Care Continuum
The research in this literature review points to housing instability as the most significant
barrier to completing the HCV healthcare continuum. All the Level III studies considered for this
review of the literature included participants that reported being homeless in the past five years,
the past year, or were currently homeless at the time that study took place. Dever et al. (2017)
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looked at socio-demographic characteristics and comorbidities related to HCV treatment
engagement among participants (n=202) from a Veteran Affairs (VA) hospital in San Diego, CA.
Dever et al. (2017) showed being homeless within the last five years was the most significant of
all socio-demographic variables (p<0.001) for not engaging in HCV treatment. Read et al.
(2017) univariate analysis showed homelessness in the past year was the only factor influencing
loss to follow up, SVR12 data, and delayed SVR12 testing. Additionally, Read et al. (2017)
showed no correlation between the loss to follow up during HCV treatment and IVDU among 72
participants reporting IVDU in the past six months.
Beiser et al., 2019 identified significant predictors of SVR12 using multivariate modeling
between HCV untreated (n=210) and treated (n=300) predominantly non-Hispanic white males
with 29% reporting homelessness. This research showed that loss to follow up and social
instability were the most common reasons for not initiating HCV treatment (Beiser et al., 2019).
Bajis (2019) evaluated SVR12 results for HCV treatment provided at a test and treat
clinic adjoined to a homeless shelter in Sidney, Australia for men age 18 and older (n=47) that
reported unstable housing (couch surfing, crisis center, shelter). A high percentage reported
being street homeless (n=28). This research showed 23 participants finished treatment, but only
a known 15 participants achieved SVR12; the other eight participants never returned to be tested
(Bajis, 2019).
Harney’s et al. (2019) study evaluated a pilot-nurse led model of care for two homeless
services looking to increase HCV treatment initiation at two inner-city homeless shelters with
one on-site clinic, located in Melbourne, Australia. The study evaluated the relationship of
initiating DAA treatment and achieving SVR12 with associated factors that could affect
treatment outcomes among 39 participants, predominantly non-indigenous males (Harney et al.,
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2019). Through the study, 24 participants started treatment and 13 achieved SVR12 (Harney et
al., 2019). Harney’s et al. (2019) research showed with significance (p < 0.05) that sleeping
rough or “on the street” prior to engaging in treatment (p < 0.019) contributed to lower rates of
treatment completion and SVR12 compared to other types of homelessness.
Fuster and Gelberg (2019) study regarding a model of HCV care for the homeless, the
majority being adult black men on Skid Row in Los Angeles, California (n = 174), were screened
and counseled for HCV infection then referred to primary care for treatment. This study showed
that having slept in a shelter the night before the clinic visit was a significant factor in attending
the primary care visit, with 74.5% of participants following through to receive test results and
initiate treatment (Fuster & Gelberg, 2019).
Lastly, qualitative research conducted by Lambert et al. (2019) in Dublin, Ireland
regarding barriers associated with attending off-site referrals for HCV treatment indicated that
housing instability was the most common barrier to attending appointments and starting
treatment. Recommendations from these studies include exploring innovative ways to increase
adherence to treatment, follow up, and SVR12 testing by bringing the care to the homeless and
tailoring services to meet their needs (Dever, et al., 2017; Grebely, 2019).
Strengths and Limitations
A major strength of the research is that all 18 studies indicate that understanding HCV
treatment barriers among the homeless is vital in developing HCV treatment models that can
decrease disease burden within this population. Research from three level I studies, and one level
III study showed how providing HCV education, regardless of the educational method,
significantly increased HCV awareness and testing. The level III studies are all of the high or
good quality and show similar results regarding qualitative data indicating that PWID and/or
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homeless are very interested in getting HCV treatment to improve their health. Both the level II
studies and the 13 Level III studies evaluating treatment models recognized the importance of
enhanced support for improving outcomes at all stages of the HCV care continuum for those who
are homeless and/or inject drugs. The research is also in agreement that being homeless affects
HCV treatment outcomes more than IVDU. Additionally, the Level II studies and the thirteen
level III studies reviewed looked at providing HCV treatment for the homeless in a variety of
countries and settings, including primary care clinics, community care clinics, SUD (substance
use disorder) clinics, and on-site homeless shelter clinics. This provided a wide range of data
regarding HCV care models currently being used to target and treat at-risk populations
worldwide, with special attention to both PWID and/or the homeless.
A major limitation of the research in this review is that there were only four studies
where the entire sample population was reporting homelessness (Bajis, 2019; Harney et al.,
2019; Lambert et al., 2019; Nyamathi et al., 2013). The other 14 studies reviewed included
research among a sampling of underserved at-risk populations which included homeless
participants. Additionally, the sample population in all 18 studies was predominantly homeless
adult men often with a ratio of men to women of 2:1 or greater. Although this might be
representative of the homeless demographic, we cannot assume that homeless adult women
would present along the HCV care continuum exactly as their male cohorts. Eight out of the 18
studies did not follow participants through treatment completion and/or discuss SVR12 results.
The aim of this literature review is to determine what type of healthcare model is most effective
in providing access to comprehensive HCV treatment with SVR12 testing for the homeless
population. It’s important to note that not all of the studies reviewed followed participants
through treatment completion and SVR12 which limits the conclusions that can be drawn
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regarding their efficacy. Additionally, in some studies, incentives such as gift cards were
provided for participants for following through with the care continuum which would not be
offered in the “real-world”. Whether this affects motivation to continue treatment and return for
SVR12 testing needs further investigation.
Another limitation is the generalizability of the outcomes to other high-income, or midlow-income countries. The actual cost of the HCV healthcare models used in the studies was not
discussed. Because the research was funded from either pharmaceutical companies or
government grants, it is unknown if any of HCV healthcare models reviewed, especially those
that included intense support, would be economically feasible in all geographical locations.
Some of the research done outside the United States (US) indicates that the medications were
paid for by the country’s government. However, HCV medications in the US research were
supplied by the pharmaceutical company or the participant’s own health care insurance. Those
who were uninsured were assisted in getting access to insurance through State aid which can add
administrative costs to providing HCV care.
Summary
This chapter includes a synthesis of major findings and recommendations of the 18
studies selected for this critical review of the literature. The Matrix method (Garrard, 2017) was
used to organize the findings. The major findings were categorized into themes related to HCV
healthcare models displayed in the research. The strengths and limitations of the studies
reviewed were also discussed.
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Chapter 4: Discussion, Implications, and Conclusion
This chapter will reexamine the clinical question, What type of healthcare model is most
effective in providing access to comprehensive HCV treatment with SVR12 for the
homeless? The synthesis of research from the 18 articles reviewed agree that underserved
populations are hard to treat due to the social and economic burdens that coincide with
homelessness. This information obtained from this literature review will be synthesized to
identify the necessary components needed in a healthcare model for treating HCV among the
homeless. Current trends and gaps in the literature will be discussed as well as recommendations
for further research. Additionally, Pender’s Model of Health Promotion in conjunction with
Fishbein and Ajzen’s Expectancy Theory and Bandura’s Social-Cognitive Theory will be used to
discuss implications and recommendations for nursing practice as it relates to providing
enhanced support in treating HCV among the homeless.
Synthesis of Literature
The clinical question guiding this review of literature is, What type of healthcare model is
most effective in providing access to comprehensive HCV treatment with SVR12 for the
homeless? Many of the models reviewed in the literature achieve treatment uptake and adherence
through a variety of methods. However, four prominent features of HCV healthcare models for
the homeless were found within the18 articles reviewed. These components included:
●

HCV POC testing and education at shelters, community clinics, and SUD clinics
increased awareness and interest in treatment

●

Treatment support through a nurse coordinator or patient navigator is essential for
getting patients through the HCV care continuum
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●

Providing the entire HCV care continuum at shelters, community clinics, and
SUD clinics had better outcomes than referring to off-site treatment

●

Homeless clients using IV drugs should be considered for treatment to decrease
disease burden
Trends in the Literature

Being homeless was found to have the greatest impact on treatment uptake and
completion. This is why a comprehensive model providing education, POC testing, evaluation,
and onsite treatment at shelters, community clinics, or SUD clinics with strong adherence
support is critical in treating the homeless population for HCV. The on-site treatment removes
many barriers, such as transportation, that exists with off-site referrals (Sena et al., 2016). The
models reviewed all mention some form of care coordination, with many using nurses as patient
navigators to assist with appointment reminders, transportation issues, administration of
medications, housing instability, and health insurance issues in an attempt to decrease barriers
that compete with treatment completion. By broadening the HCV treatment care team from offsite specialists to advanced practice practitioners (APP) and general practitioners (GP) staffing
community clinics and homeless shelters, access to HCV treatment is occurring globally
(Grebely et al., 2019). Additionally, due to the high prevalence of IVDU among the homeless,
many of the reviewed HCV treatment models are testing and treating the homeless patients with
HCV at SUD clinics as well. Regardless of being homeless, using drugs or having a mental
illness, research shows that there is still a desire to seek healthcare (Fuster & Gelberg, 2019).
This desire for good health helps support the research seen in this review indicating that those
who use IV drugs are able to achieve SVR12. Additionally, treating people currently injecting
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drugs has the potential to decrease disease burden at greater rates and meet the WHO’s goal
(Grebely, 2019).
Gaps in the Literature
RCT trials regarding treatment models were lacking, perhaps due to the ethics of treating
an underserved population known to be facing an HCV epidemic. Many of the studies showed
treatment completion and even SVR12 was possible among the homeless even though treatment
uptake and completion remain suboptimal when compared to populations who are not homeless.
This is most likely due to their complex social needs (Bajis, 2019). More studies regarding HCV
treatment and concurrent homelessness would be useful in understanding “real-time” treatment
barriers for this population. Additionally, more research is needed to fully understand how best
to tackle HCV treatment for street homeless versus sheltered homelessness. Enhanced support
for the homeless was utilized in several of the studies, but more qualitative research would be
useful in understanding what component of the support model is most impactful for treatment
completion and controlling loss to follow up. Consequently, it’s not fully understood at this time
if treating people who are homeless and concurrently using IV drugs without SUD support is
effective. More research is also needed before knowing whether treating PWID will decrease the
burden due to the risk of reinfection (Grebely et al., 2019). In regard to cost-effectiveness and
treatment uptake, additional research comparing countries where government funding is
available for HCV treatment versus countries where medical insurance enrollment is required
would provide important information on tackling the insurance barrier seen in the U.S.
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Integration of Theoretical Framework
The application of Pender’s Health Promotion Model (HPM) to the WHO’s goal of
decreasing HCV infection significantly worldwide by 2030 can be used to assist nurses in
making this goal a reality. According to McCullagh (2016), HPM has not been tested in
situations with unstable living conditions. However, there is still much to consider about this
nursing theory and how it applies to the HCV treatment models for the homeless. According to
Pender’s HPM, individual characteristics and experiences will influence behavioral changes
related to health (McCullagh, 2016). This helps to explain why some clients may initiate HCV
testing and treatment after receiving HCV education and others decide not to. The research
shows how enhanced support helps a client through the HCV continuum. Pender’s theory
suggests that nurses can be the agent that helps lead the client through behavioral changes that
promote improved health (McEwen, 2014). Regarding HCV support, the nurse can use the HPM
to assess clients for perceived benefits, perceived barriers, perceived self-efficacy, as well as
interpersonal support and situational influences that may affect their ability to commit to HCV
treatment (McCullagh, 2016).
Perceived Benefit
From the qualitative study done by Williams et al. (2019), clients associated being cured
of Hepatitis C with an opportunity to erase the stigma of being a drug user and obtain stable
housing, employment, and healthy living. Incorporating questionnaires regarding quality of life
provides important information about how the client feels they will benefit from HCV treatment
and provide motivation for testing and treatment.
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Perceived Barriers
As seen by the research in this review, people who are homeless with HCV infection
have many competing factors that prevent them from making HCV treatment a priority. Nonpublished research results from focus groups conducted among HCV infected homeless adults in
Minneapolis, Minnesota indicated that main barriers regarding testing and treatment centered
around perceived susceptibility to HCV, medication side effects, medical mistrust, competing
priorities, and the negative impact of substance use. Nola Pender recognized that there are
immediate competing demands and preferences that distract individuals from engaging in health
promotion activities (McCullagh, 2016). For the homeless, finding shelter due to extreme cold,
maintaining a job, or not feeling safe are significant reasons why an individual might not show to
a clinic visit for HCV testing or treatment initiation, especially in the absence of feeling ill.
Perceived Self-Efficacy
To understand the effects of homelessness on an individual and their ability to partake in
health promotion, the provider must understand if the person believes they are capable of
completing the HCV care continuum. According to Pender, self-efficacy is “…the confidence in
his or her ability to successfully carry out an action” and its behavioral cognition that affects
one’s commitment to a plan of action (McCullagh, 2016, p. 230). If the client is feeling displaced
by their homeless, their confidence in tackling HCV treatment may wane.
Interpersonal and Situational Influences
Pender’s HPM identifies interpersonal and situational influences as being able to directly
and indirectly influence a plan of action (McCullagh, 2016). In the setting of homelessness,
shelter clinics with an enhanced clinical support system for treating HCV may provide missing
social support, which is identified as a basic human need that proves beneficial in helping one
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cope (Pender, Murdaugh, & Parsons, 2011). Hodges et al. (2019) research showed that HCV
shared medical appointment (SMA) among clients with similar socioeconomic demographics
and characteristics significantly increased treatment completion. Clients that receive enhanced
support during HCV treatment may benefit from the social pressures of committing to a plan of
action.
Nursing Implications and Recommendations
Providing HCV models with enhanced support requires resources and sustainability.
Nurse educators are at the forefront of educating new nurses about HCV and the populations
who are at risk for infection. Ensuring public health courses include HCV education about “atrisk” populations and the treatments available arms them with the necessary information needed
to provide primary, secondary, and tertiary prevention. Nurses must take an active role in
screening for HCV whenever appropriate to ensure their patients are informed to make good
decisions regarding their health. Additionally, the nursing profession, with the addition of
advanced practice nursing, has the ability to provide services through outreach initiatives or a
referral network for HCV education, testing, and treatment. Nurses can identify locations where
the homeless frequent, such as drug treatment facilities, community clinics, shelters, needle
exchange programs, and food services within their own community to promote HCV awareness.
Once treatment is started, having a convenient place for clients to access care on a daily, weekly,
or monthly basis is a critical component for enhanced models and can be supported solely by a
nursing team (Harney et al., 2019).
Community models for HCV testing and treatment involve funding that must be
supported and sustained. Nurses can explore grants that provide funding for these efforts, as well
as lobbying legislators through union initiatives for better access to HCV care for the homeless.
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Additionally, buy-in from the shelter staff and community clinics along with effective planning
and implementation will be essential for an enhanced HCV healthcare model to succeed.
Nursing Research
Due to the transient nature of the homeless and the difficulty in obtaining SVR12 results,
research regarding HCV in this population should focus on how to get more HCV infected
homeless tested and through treatment. The high percentage of cure rates with DAA medications
provides reassurance that a significant number could be cured as long as the medication is taken
correctly and the treatment course is finished (J. Powell, personal communication, December 23,
2019). For this reason, research for HCV enhanced support models for the homeless should
continue to explore how to obtain higher rates of treatment uptake and completion with EOT
pathology. Although every effort should be made to capture SVR12 data among the homeless,
the reality is that having someone who is a transient return for testing three months posttreatment is difficult.
More randomized control trials and quasi-experimental research is needed regarding what
nursing interventions within a support model are most effective in increasing HCV testing and
treatment uptake. This research would be useful in providing a standard nursing support model
that could be adopted by other community and shelter clinics treating HCV. Ideally, having a
data collection tool that captures the physical and mental health benefits of being cured of HCV
could be beneficial in encouraging treatment among the homeless.
Conclusion
Navigating homeless patients through HCV care continuum requires a healthcare model
that controls the barriers preventing treatment uptake and adherence. From the trends in research,
the HCV healthcare model that will be most effective for achieving SVR12 among the homeless
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will provide the HCV continuum in one location, preferably a clinic adjoined with a homeless
shelter providing enhanced support to control barriers to treatment. In addition, due to the high
prevalence of injection drug use among the homeless, special consideration must be given to
treating HCV regardless of past or present use of IVDU to decrease disease burden. Shifting the
treatment team from a Hepatologist to a broader treatment team that includes general
practitioners or advanced practice providers has allowed HCV care to occur in a location
convenient for the homeless to access. Broadening access to testing and treatment along with the
oral DAA medications has dramatically changed our ability to treat HCV in the homeless.
However, advanced treatments and broader access alone cannot control disease burden among
this population. Addressing the social and interpersonal barriers through an enhanced support
model for HCV care that is reinforced by evidence-based research has the potential to be an
essential tool in decreasing disease burden among the homeless worldwide.
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Appendix A- Matrices
Source: Alavi, M., Poustchi, H., Merat, S., Kaveh-ei, S., Rahimi-Movaghar, A., Shadloo, B.,
…Malekzadeh, R. (2019). An intervention to improve HCV testing, linkage to care, and treatment among
people who use drugs in Tehran, Iran: The ENHANCE study. International Journal of Drug Policy, 72,
99-105. doi:10.1016/j.drugpo.2019.07.002
Purpose/Sample
Purpose:
To trial an HCV
treatment model,
ENHANCE, that
encouraged and
increased availability
of DAA treatment
among former and
current drug users
(PWUD).
Sample/Setting:
Tehran, Iran
Opioid substitution
treatment (OST)
clinics, communitybased drop-in centers,
homeless reception
center.
n=652
158 participants from
the homeless
reception center.
Johns Hopkins
Evidence Appraisal
Level of Evidence:
III
Quality: Good

Design
(Method/Instruments)
Non-experimental study.

Results

100% of PWID, in the last
Participants agreed to
12 months, initiated
participate in the
treatment. 8/13 completed
ENHANCE interventions treatment and achieved
– onsite HCV rapid
SVR 12.
antibody testing,
venipuncture for HCV
-22/158 homeless with
RNA testing, and nondetectable HCV RNA
invasive liver fibrosis
initiated treatment. All 22
assessment, linkage to
completed treatment and
care, and treatment
had undetectable HCV
initiation among PWUD. RNA at the end of
treatment. None could be
ENHANCE Modelfollowed for SVR12.
Self-reported behavioral
survey was collected
HCV knowledge was poor
which included:
– but 97% surveyed were
demographics collected, willing to be treated after
drug use history, alcohol HCV Education.
consumption, HCV and
liver disease knowledge, 87% of all HCV RNA +
and desire to receive HCV participants initiated
treatment.
treatment.
SVR at 12 weeks.
Conclusion:
A community- based HCV
Homeless Shelter –
care model can provide a
Reunited with family or high level of adherence
referred homeless shelter support and SVR 12 for
for stable housing.
marginalized populations,
GP or Nurse dispensed
including the home.
medications weekly or
daily and monitored HCV
treatment.

Strengths/Limitations
Strengths:
-Provides a healthcare
model that includes
medication dispensing can
provide high rates of
treatment initiation and
completion.
Limitations:
Interest in treatment may
have been increased since
the medication was free.
Participants on OST
Clinical care practices
may be hard to transfer
unless testing and
treatment are free.
Unable to follow the
homeless participants for
SVR 12.

Author Recommendations
Providing more HCV care models for treating PWID is recommended.
Implications: Models supporting weekly or daily dispensing of medication can be more costly but seem
to provide a higher adherence to treatment and SVR 12.
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Source: Bajis, S. (2019). Hepatitis C virus testing, liver disease assessment and direct‐acting antiviral
treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The
LiveRLife homelessness study. Journal of Viral Hepatitis, 26(8), 969-978. doi:10.1111/jvh:13112
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Non-experimental.
n=47/202 or 23% of those Strengths:
enrolled had detectable
Evaluate a
Education provided over HCV infections.
community-based
several campaign days.
n=47
Evaluates only a homeless
model of care that
- 93% reported injecting
population.
integrates health
Enrollment included on- drugs in the previous
promotion and liver site point of care HCV
month. 57% injected daily. Incorporates a
fibrosis testing for
antibody testing, self- 43% had moderate to
comprehensive model of
HCV treatment uptake reported behavioral
significant fibrosis
care for HCV.
among homeless
survey, HCV RNA testing, -60% reported unstable
people.
Fibroscan testing, and
housing/street homeless.
Findings are consistent
treatment.
-65% who initiated DAA with other research
treatment achieved SVR
showing HCV+ homeless
Sample/Setting:
Participants were
12.
have increased risk for not
categorized between
-80% of participants who being linked to care and
n=202
unstable housing (no
received weekly dispensing “lost to follow up.”
men > age18
home, couch surfing,
of medications achieved
receiving services
shelter, hostel, crisis
SVR 12.
from an inner-city
center, boarding house)
-Observed higher uptake
community center
and stable housing (own associated with participants Limitations:
with a daily nurse-led home, rent apartment/flat). on OST (opioid substitution
clinic in Sydney,
therapy). Not shown to be Small sample size
Australia. Support
CI of 95% were used to
significant (p=0.239).
Men only study
was provided twice a analyze the factors
Not easily generalized to
week by general
associated with HCV
Conclusion:
other inner-city homeless
practitioner. Homeless treatment uptake.
HCV treatment uptake
shelters.
shelter adjoined to the
completion among
May have missed other
clinic.
P < 0.05 was statistically homeless people continue homeless (sleeping rough
significant.
to be “suboptimal” most
population) who are
Johns Hopkins
likely due to complex
harder to reach that could
Evidence Appraisal
barriers, such as “social
change study results.
needs and competing
Level of Evidence:
priorities” (Bajis, 2019,p.
III
977)
Quality: Good
Author Recommendations: Strategies to enhance HCV testing and treatment needs to be enhanced
among the homeless.
Implications: Programs that combine HCV treatment with housing resources, opioid substitution
therapy, and mental health services could help improve treatment uptake and adherence.
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Source: Beiser, M. E., Smith, K., Ingemi, M., Mulligan, E., & Baggett, T. P. (2019). Hepatitis C
treatment outcomes among homeless-experienced individual a community health centre in
Boston. International Journal of Drug Policy, 72, 129-137. doi:10.1016/j.drugpo.2019.03.017
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
-Loss to follow up and
Strengths:
Non-experimental
social instability were the
most common reasons for Large sample size of
To assess the HCV
Review of data with data not being treated.
homeless patients at the
cascade of treatment
time of their treatment.
including SVR 12 and analysis.
-285/300 completed
reinfection rates among
Multivariate modeling treatment.
Recognizes insurance
homeless patients
was used to identify
receiving adherence
-255/285 achieved SVR12. issues, such an
important predictors of
interruption in coverage,
support through a
-78% reported no missed as a factor in medication
community care model achieving SVR 12.
adherence.
doses
in in Boston, MA.
Sample/Setting:
n=510 HCV infected
n=210 untreated
n=300 homeless
experienced patients
received HCV treatment
between January, 2014 –
March, 2017
80% were male,
52.3% were non-white,
29% were homeless at
the time of treatment.
30.7% stayed at
transitional treatment
facilities.
Johns Hopkins
Evidence Appraisal
of Evidence:
Level: III
Quality: High

-3.7% were lost to follow
up during treatment.
-87.1% treat opioid use
disorder (OUD) achieved Limitations:
SVR 12.
Community care model
requires funding that may
-81.8% with untreated
OUD achieved SVR 12. not be available in all
communities.
-Medication missed doses
where more likely due to
insurance changes while
on treatment (p<0.029).
Conclusion:
Adherence support through
a designated nursing model
increases medication
compliance in HCV
treatment in the homeless
population.

Author Recommendations: Continue research in the area HCV treatment models for the homeless,
including on-site clinics, mobile medical units, as well as increasing collaboration with addiction
medicine and behavioral health providers.
Implications: Community care models that provide adherence support are key factors in keeping HCV
infected homeless patients cured.
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Source: Coyle, C., Moorman, A., Bartholomew, T., Klein, G., Kwakwa, H.,Mehta, S., & Holtzman, D.
(2019). The hepatitis C virus care continuum: Linkage to hepatitis C virus care and treatment among
patients at an urban health network, Philadelphia, PA. Hepatology, 70(2), 476-486.
doi:10.1002/hep.30501
Purpose/Sample
Purpose:
Compare HCV
treatment and cure
rates between HCV
test and treat
healthcare centers and
HCV testing only
healthcare centers in
an urban network in
Philadelphia, PA.

Design
(Method/Instruments)

Results

Strengths/Limitations

Strengths:
-Highest prevalence of
HCV + antibody and HCV Large sample size
RNA detection seen at the Strong statistical analysis.
Chart review of all FQHC center serving the
Long time frame – could
patients testing HCV
homeless.
see how treatment trends
antibody positive was
had changed from 2014 to
performed.
2017.
-The test and treat centers
Multivariate logistic
had SVR 12 achievement Reflects other research
regression was used to
rates 6 times that of the
findings that high HCV
Sample/Setting:
identify what factors
other “test only” sites.
infection rates are
Five federally funded interrupted the care
prevalent among the
qualified health
continuum at two crucial -Referring outside the
homeless population.
centers (FQHCs).
steps.1) medical evaluation health center for treatment
HCV antibody +
2) liver disease staging.
was associated with breaks
adults (18 and older).
in the care continuum.
Limitations:
Four FQHCs
Covariates such as
including one center demographics, injection Conclusion:
Expanding facilities that
treating homeless
drug use, incarceration,
test and treat may not be
patients exclusively and homelessness were
Providing on-site HCV care feasible in every city.
where test only
evaluated using a p value is essential in removing
centers who referred of <0.10.
barriers such as
out for HCV
transportation and
Homeless population was
treatment.
SVR assessment and SVR reluctance to seeking care. not treated at test and treat
N=885 chronically
12 outcomes were assessed
facility which might have
infected with HCV
cumulatively for all sites.
contributed to lower
Funding and support are
adherence & not
Johns Hopkins
crucial in being able to
achieving SVR 12.
Evidence Appraisal
support HCV treatment in
Level of Evidence:
every situation.
III
Quality: High
Non-Experimental

Author Recommendations: Expand test and treat centers to avoid loss to follow up from referring
outside for evaluation and treatment.
Implications: Increasing “test and treat” sites is more feasible now with the ability of primary care
physicians to prescribed DAA medications.
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Source: Coyle, C., Viner, K., Hughes, E., Kwakwa, H., Zibbell, J. E., Vellozzi, C., & Holtzman, D.
(2015). Identification and linkage to care of HCV-infected persons in five health centers -Philadelphia, Pennsylvania, 2012-2014. Morbidity & Mortality Weekly Report, 64(17), 459-463.
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584550/
Purpose/
Design
Results
Strengths/
Sample
(Method/Instruments)
Limitations
Purpose:
The
use
of
reflex
testing
Non-Experimental
To initiate a
increased overall testing Strengths:
- National Nursing
process between 5
for HCV confirmation to
Centers Consortium
federally qualified
Provides feasibility for
96.3%.
(HHCC) provided
health centers
targeting HCV high- MA testing increased
Hepatitis C education
(FQHC) serving
HCV diagnosis by 6.3%. risk populations,
using a HCV expert to 5
the homeless and
providing testing and a
- Linkage to care
sites.
public housing
pathway to treatment.
coordination helped
- Eligible patients were
residents that
increase the patients who
born 1945-1965 (Baby
encourages testing
actually received their Shows a positive
Boomers),
injection
for Hepatitis C
+HCV results by almost relationship between
drug users, and/or
(HCV) in high-risk
70%, referrals for
homeless.
groups and
care coordination and
treatment by 50% and
Medical
Assistants
connects patients
patient compliance.
to care
patients actually seen by
(MA) initiated HCV
coordination.
a provider increased
testing/education once
Limitations:
almost 30%.
identifiers were
Sample/Setting:
- Sites that provided
confirmed.
4.514 patients
Didn’t follow patients
testing and treatment
- Used reflex testing on +
were tested for
versus just testing with a through treatment and
HCV antibodies to test
HCV antibodies
cure.
referral to treatment,
immediately for HCV
across 5 sites
linked more patients to
RNA (Chronic virus).
(FQHC) in
coordinated care
Electronic
Medical
Philadelphia, PA.
specialist.
Record (EMR) was
used
to
remind
Johns Hopkins
Conclusionproviders that patient’s
Evidence
Routine HCV testing can be
Appraisal
+HCV patients should
easily incorporated into clinic
Level of
be referred for care
visits with the help of a wellEvidence: III
coordination.
coordinated process.
Quality: Good
Author Recommendations: To provide continued research in larger public health care systems using
this model to test, educate, and treat patients at risk for HCV.
Implications: Community healthcare agencies are positioned to help create access for high risk
populations to get tested and treated for HCV when they partner with public health agencies in
providing support services to guide patients through the process.
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Source: Dever, J., Ducom, J., Ma, A., Nguyen, J., Liu, L., Herrin, A., . . . Ho, S. B. (2017). Engagement in
care of high-risk hepatitis C patients with interferon-free direct-acting antiviral therapies. Digestive
Diseases & Sciences, 62(6), 1472-1479. doi:10.1007/s10620-017-4548-4
Purpose/Sample
Design
Results
Strengths/Limitations
Method/Instruments
Purpose:
-Homeless within the last Strengths:
To determine if patient
Non-experimental
5 years was the most
Captured homeless, at
risk population.
engagement to more tolerable
significant of all sociooral direct-acting antiviral
-Outreach letters and demographic variables
Characteristics regarding
(DAA HCV treatments are calls were made to
(p<0.001) for nonbarriers to HCV
influenced by a patient’s
patients informing them engagement.
treatment similar to other
socio-demographic
about eligibility to
-Only 24 % of homeless studies.
characteristics and
receive HCV treatment. engaged in care.
comorbidities.
- Multivariate regression Limitations:
Patients had already
-Participants in groups analysis showed that
been tested positive
Sample/Setting:
were divided between active alcohol/drug use
n=202
those responding
was significant to one’s HCV prior to being
Patients diagnosed with HCV (Engaged, n=88) and ability to engage in HCV contacted.
Sample size might have
and had Fibrosis scores of 4 those not responding care.
within the HCV registry of (non-engaged, n=114)). -Groups had similar # of been lower if patients
required testing to
the Veterans Affairs (VA)
comorbid disorders,
participate.
hospital in San Diego, CA
-Using Chi-square,
distance to travel, and
that had never been seen by a Fisher’s exact and
mental health diagnoses. Low percentage of
HCV clinic provider or were Wilcoxon rank sum
-COPD (p<0.03) was the homeless engaging in
care
lost to follow-up care.
tests along with
most significant
regression analyses was comorbidity for nonAssumes “non-engaged”
Johns Hopkins Evidence
completed to show
engagement.
are those not interested
Appraisal
but could be that they
variables that were
Conclusion:
Level of Evidence: III
just moved, don’t have a
significant (p< 0.05) in High percentage of
Quality: Good
engaged (responded to patients were linked to
permanent address (since
outreach efforts) versus HCV treatment or enrolled homeless was the more
significant variable) or
non-engaged (didn’t
in HCV clinic over the
got a new phone number
respond) in HCV care. course of the study.
74% of patients treated
with DAA achieved a
cure.
Author Recommendations: Further research studies investigating barriers related to receiving access, as
well as innovative ways for healthcare professionals to provide access to DAA treatments is needed on
both local and national levels. Using mailers and phone calls may not be the best way to engage homeless
patients in HCV treatment.
Implications: This study provides evidence that linking HCV patients to treatment with DAA provides
high cure rates. The concerning issue is that effective outreach, homelessness, alcohol/drug use and some
comorbidities are strong barriers to linking patients to treatment.
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Source: Fuster, D., & Gelberg, L. (2019). Community screening, identification, and referral to primary
care, for hepatitis C, B, and HIV among homeless persons in Los Angeles. Journal of Community
Health, 44(6), 1044-1054. doi:10.1007/s10900-019-00679-w
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Strengths:
Non-experimental
-74.5% testing positive for
To test a model of
correlates study.
an infection were seen at a Large sample size
community-based
primary care clinic.
screening,
Participants were chosen
Participants were selected
identification, and
though simple random or
randomly from a variety
counseling for
systematic random
-Having slept in a shelter of homeless shelter and
homeless clients with sampling.
the night before the clinic food programs.
referral to return to a
visit had a 95 % CI and
primary care clinic in Questionnaire regarding showed statistical
one month for
barriers to follow up and significance in attending
Limitations:
secondary prevention serum blood testing was the clinic visit.
and treatment for
done on all participants.
Long-term outcomes such
HIV, HCV, and HBV.
-There was no evidence
as treatment and SVR
Linkage to primary care that homelessness, drug or were not assessed.
Sample/Setting:
for positive HIV, HCV,
alcohol use, or mental
n=172
and HBV was provided for illness affected care
Unable to generalize
Majority were adult 172 adults.
seeking.
finding due to the high
men
intensity of homeless
Homeless population Reminders cards and calls
services found in Skid
in Skid Row, Los
regarding clinic
Row.
Angeles
appointments were done Conclusion:
testing positive for
for all participants.
Sleeping in a shelter
Patients were
one of the following:
provides stability needed to compensated for
HIV, HCV, HBV.
Chi-square and t-test
attend health services if
following through with
analysis was performed on they are within close
the study parameters.
Johns Hopkins
categorical and continuous proximity to the shelter.
Evidence Appraisal variables, respectively.
Study was done when
Level of
patients would have been
Evidence: III
Logistic regression
treated with older
Quality: High
analysis was used to find
interferon-ribavirin drugs
predictors related to
versus the more tolerable
following through on oneDAA agents.
month scheduled followup.
Author Recommendations: Future work is indicated in testing, treating, and counseling with primary
care referral for HBV, HIV, HCV.
Implications: Being sheltered is a key factor in getting homeless people to seek primary healthcare
services.
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Source: Grebely, J., Hajarizadeh, B., Lazarus, J. V., Bruneau, J., & Treloar, C. (2019). Elimination of

hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention,
treatment, and care for all. International Journal on Drug Policy, 72, 1-10.
doi:10.1016/j.drugpo.2019.07.016
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Systematic Review
-Understanding barriers to Strengths:
Provide a summary of
care is necessary to
research regarding
providing equitable access. Comprehensive review of
Hepatitis C infection
-Point of care testing and studies looking at HCV
among PWID in an
treatment increase uptake treatment in PWID.
attempt to provide
HCV treatment.
equal access to
-Lack of knowledge about
testing, treatment, and
HCV prevents testing and
care.
treatment.
-Lower SVR12 compared
Sample/Setting:
to clinical trials are due to
21 original research
loss to follow up, not
Limitations:
studies (combination
virologic response.
of RCTs, quasi-Recent injecting drug use Summary based. No
experimental and
didn’t affect SVR 12.
meta-analysis provided.
nonexperimental).
-HCV infection is highly
2 Systemic reviews
prevalent among the
3 Expert opinion.
homeless – global rates of 4
to 36%. High rates of drug
use in this population yields
Johns Hopkins
lower treatment uptake.
Evidence Appraisal
-Risk for reinfection must
III
be considered.
-Erasing stigma needs to be
Quality: Good
prioritized.
Conclusion
-Identified the “cascade of
care” for HCV infection as
living with HCV,
diagnosed with HCV,
linked to care, treated, and
cured.
Author Recommendations: HCV treatment programs must be developed in different settings, especially
where resources are lacking such as low and middle-income countries, and underserved populations.
Implications: The best way to tackle the HCV epidemic is to tailor treatment programs to the target
population.
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Source: Harney, B. L., Whitton, B., Lim, C., Paige, E., McDonald, B., Nolan, S., …Doyle, J. S. (2019).
Quantitative evaluation of an integrated nurse model of care providing hepatitis C treatment to people
attending homeless services in Melbourne, Australia. International Journal of Drug Policy., 72, 195-198.
doi: 10.1016/j.drugpo.2019.02.012
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Sleeping rough (literally on Strengths:
Non-experimental study the street) contributed to
Evaluate a pilot-nurse
lower rates of treatment
Focus was homeless
led model of care for
completion and known
population only and HCV
two homeless services Two outcomes were
SVR 12 when compared to treatment uptake.
looking to increase
evaluated
other types of
HCV treatment
Looked at differences in
1) Initiation of any homelessness.
initiation.
HCV uptake and SVR in
DAA medication.
17/21
those
considered
two types of
2) Achieving SVR
sheltered
completed
homelessness.
12.
treatment.
Questionnaire was given to 7/18 living rough
participants that provided completed treatment.
information regarding
injection drug use and
SVR12 test were available
sleeping accommodations for 60% of those treated –
that could possibly affect which all showed a cure.
outcomes.
This study aligns with
Logistic regression
findings from other studies Limitations:
methods were used to
that showed that testing for
examine these factors.
Johns Hopkins
SVR is sub-optimal in this Small sample with no
Evidence Appraisal
population, as well as
mental health questions
treatment uptake.
Level of Evidence:
Pilot program with
III
Conclusion:
funding – not necessarily
Quality: Good
Nurse-led models of care transferrable to other
can be effective in
organizations.
engaging clients.
for HCV treatment in the
homeless population.
Sample/Setting:
Two inner-city
homeless services,
with one on-site
clinic.
n=39
64% male

Author Recommendations: Continue research in tailored treatment services for the homeless.
Implications: Same day testing and treatment initiation for HCV for the homeless may increase
treatment uptake and continued tailoring of services may encourage SVR follow up.
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Source: Hodges, J., Reyes, J., Campbell, J., Klein, W., & Wurcel, A. (2019). Successful implementation
of a shared medical appointment model for hepatitis C treatment at a community health center. Journal of
Community Health, 44(1), 169-171. doi:10.1007/s10900-018-0568-z
Purpose/Sample

Design
(Method/Instruments)

Purpose:
To test the feasibility
of a shared medical Non-randomized, Quasiappointment (SMA) experimental study
in HCV treatment
provide by nonspecialist providers in This study looked at SVR
a community health 12 rates between patients
center to help improve who selected to use SMA
self-care and
model versus those who
adherence as it has
selected an independent
been shown to do for appointment model.
other chronic diseases.
Confidence Intervals were
Sample/Setting:
done to ensure accuracy of
Community health
results.
center on Cape Cod
serving a population
with high rates of
homelessness,
substance abuse and
mental illness.
N=102
64% male
Johns Hopkins
Evidence Appraisal
Level of Evidence:
II
Quality: Good

Results
SMA76% continued after one
appointment.
99% Completed full
treatment course.
91% Achieved SVR.
Individual appointment88% completed treatment
69% achieved SVR.

Strengths/Limitations
Strengths:
Identifies the how peer
support may decrease
HCV stigmas and
encourage healing.
Encourages nonspecialized treatment of
HCV for more accessible
care.
Limitations:

Conclusion:
Participants in the SMA
model were 6 times more
likely to achieve SVR 12
compared to those who
selected the individual
appointment.

SMA was provided to
patients with similar
socioeconomic
demographics and
characteristics.
Smaller sample size, one
location.
Study was done where
substance use disorders
were managed allowing
participants to be more
adherent to HCV
treatment and thus, likely
yielding higher SVR 12
rates.

Author Recommendations: More research is needed to know if SMA can impact HCV adherence and
SVR 12 so there can be buy-in from stakeholders, clinicians, administrators, insurers, and patients.
Implications: The SMA model identifies a support system that could be crucial for improving treatment
adherence among the homeless and the encouragement to return for SVR12 testing.

62

Source: Lambert, J. S., Murtagh, R., Menezes, D., O'Carroll, A., Murphy, C., Cullen, W., . . . Van Hout, M.
C. (2019). 'HepCheck Dublin': An intensified hepatitis C screening programme in a homeless population
demonstrates the need for alternative models of care. BMC Infectious Diseases, 19(1), 1-9.
doi:10.1186/s12879-019-3748-2
Purpose/Sample
Purpose:
To provide
characterization of
HCV burden for
homeless individuals
to provide an
“integrated” care
model for HCV
treatment between
primary care and
specialists.

Design
(Method/Instruments)

Results

Strengths/Limitations

Strengths:
-46 referrals to specialists, -21 attended at least two
HepCheck Dublin part of a
Participants recruited over appointments, seven
larger European initiative to
a 19 -month period from received liver testing, and drive HCV testing and
11 Safety net services
two out of 199 completed treatment among the
(offering primary care and treatment.
homeless.
methadone treatment) in
Dublin, Ireland and in-HCV + known group
A large sample size recruited
reach services (coffee
previously referred to
from various homeless
shops, mobile units,
specialists cited unstable settings.
needle-exchange
housing accommodation as
Sample/Setting:
programs).
the most common barrier to Highlights the complexities of
n=538 people
not attending an
HCV care for the homeless in
Screened
Questionnaire were used to appointment and accessing Dublin which parallel
78% male
collect data from both
treatment.
complexities world-wide.
Median age 36
groups.
-78% living a hostel, others
n=199 HCV +
were couch surfing,
Housing instability is
(112 new and 87
A convenience sample
sleeping rough)
recognized as a major barrier
known)
(n=48) of participants with 85% homeless longer than to HCV treatment retention.
known HCV + were given one year
Johns Hopkins
a 79 open-ended
-42% saw GP once/week Limitations:
Evidence Appraisal questionnaire exploring
(reasons not specified)
Not all participants had access
Level of Evidence: reasons for not following -50% who started
to a “keyworker” to assist in
III
up for treatment.
specialized, discontinued the referral process.
Quality: A
before completing
Unable to send reminders to
Follow through to
treatment.
all participants.
attending three specialist
Study was done during a
appointments were tracked Conclusion:
homeless crisis in Dublin,
and analyzed using
HCV referrals and
which may have complicated
unadjusted negative
attendance at follow up
the process for HCV referrals.
binomial regression
care are challenges for the
(NBR).
homeless.
Current referral system in
Ireland is not adequate.
Author Recommendations: The homeless population in Dublin could be better served through a
community-based treatment model of care.
Qualitative study

Implications: Creating community-based clinics for treating the homeless for HCV would alleviate some of
the major challenges created by a specialist only referral system in Dublin, Ireland.
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Source: Larios, S. E., Masson, C. L., Shopshire, M. S., Hettema, J., Jordan, A. E., McKnight, C., . . .
Perlman, D. C. (2014). Education and counseling in the methadone treatment setting improves knowledge of
viral hepatitis. Journal of Substance Abuse Treatment, 46(4), 528-531.doi: 10.1016/jsat.2013.10.012
Purpose/Sample
Design
Results
Strengths/
Method/Instruments
Limitations
Purpose:
Randomized Control Trial
Strengths:
(RCT) Experimental
-Knowledge scores for
To compare effectiveness of
all Hepatitis education RCT eliminates
providing Hepatitis
Participants were randomized increased from baseline unintended bias.
education using a
Group characteristics
into two intervention groups to immediately
motivational enhanced
were similar between
after completing baseline
following education
interviewing method for
interviews.
and continued through both sites.
education and counseling
the 3-month follow up Knowledge retention
1) Standard Hepatitis
versus a standard didactic
was examined.
at both sites.
education and
manner.
counseling provided -Knowledge retention Results are similar to
was greater at 3-month other studies that have
by nurse (control).
Sample/Setting:
post
intervention than evaluated MI
2) MI-enhanced hepatitis
enhanced Hepatitis
immediately
after.
education and
education.
n= 440 adults receiving
-No significant
counseling presented
methadone maintenance
difference between
by staff trained in MI
treatment in two Methadone
baseline characteristics
techniques during a 4- and HCV prevalence
clinic sites (New York city
hour session
& San Francisco) who were
existed between groups.
(intervention).
Limitations:
18 years or older, Hepatitis C
Conclusion:
(HCV) negative or unknown,
Identical educational topics
Study did not address
There were no
or if HCV + had never
were used in both groups and
whether increase in
additional gains in
received treatment, able to
administered over a 3 -month
knowledge led to
HCV knowledge
consent.
time frame.
desire to be tested and
associated with MI
treated.
enhanced techniques
2 educational sessions were
when compared to the
Johns Hopkins Evidence
done for each group
nurse led intervention.
Appraisal
Level of Evidence: I
ANOVAs were used to
Quality: High
analyze time as a predictor of
changes in HCV knowledge.

Author Recommendations: Further research using facilitators that have extensive MI training in MI
enhanced methods to facilitate HCV education is recommended.
Implications: Traditional methods for educating at risk or infected patients about Hepatitis are effective and
can be applied without additional training.
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Source: Masson, C. L., Delucchi, K. L., McKnight, C., Hettema, J., Khalili, M., Min, A., … Perlman, D. C.
(2013). A randomized trial of a hepatitis care coordination model in methadone maintenance treatment.
American Journal of Public Health, 103(10), e81–e88. doi:10.2105/AJPH.2013.301458
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose: To
Randomized control trial -40 % were homeless in Strengths:
compare outcomes
the past 6 months from
Both groups received
both groups
from a care
Provides insight on how to
individual 2-session
use existing drug treatment
coordination
-Roughly 70% had
Hepatitis and HIV pretest injection drug use
facilities to assist in the testing
intervention to
improve linkage to counseling, blood testing, -Intervention group
and treatment for populations
received HCV evaluation at risk for hepatitis.
Hepatitis A (HAV) and posttest counseling
sooner, more likely to
and Hepatitis B
-Intervention group
complete vaccinations
(HAB) vaccines and (n=244) – on-site
and HCV and HBV
Hepatitis C (HCV) vaccination, and
motivational interviewing treatment
Limitations:
evaluation.
(MI) -enhanced counseling, recommendations, have
greater reductions in
and off-site clinical
Low external validity to other
evaluations for 6 months. alcohol use.
Sample/Setting:
settings besides drug treatment
-Control group (n=245) – -Co-infection with HIV centers.
increased likeliness for Looks at data for linkage with
counseling without
489 participants
motivational interviewing HCV evaluation.
initial evaluation, not
from methadone
-Individuals reporting
compliance for treatment,
treatment clinics in enhanced style, off-site
New York and San referral for vaccination and homelessness were most sustained viral response
likely to not follow
hepatitis evaluation.
(SVR12).
Francisco.
through with HCV
– t-test and Pearson’s test evaluation.
Conclusion:
applied to compare
Johns Hopkins
Evidence Appraisal variables.
-Providing on-site
vaccination for
HAV/HBV at drug
Level of Evidence: I - Logistic regression
treatment facilities has
models were used to
Quality: High
compare outcomes between the potential to increase
series compliance.
the two groups.
Intervention group’s
compliance was better
overall, but it is unclear
which element of the care
coordination helped the
most.
Author Recommendations: More research is needed to understand whether the care coordination model is
cost effective compared to outcomes it provides.
Implications: This study shows how Hepatitis C evaluation can be more effective when done onsite at
methadone treatment facilities than at off -site referrals, especially among the homeless.
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Source: Norton, B. L., Voils, C. I., Timberlake, S. H., Hecker, E. J., Goswami, N. D., Huffman, K. M., . . .
Stout, J. E. (2014). Community-based HCV screening: Knowledge and attitudes in a high-risk urban
population. BMC Infectious Diseases, 14(1), 74. doi:10.1186/1471-2334-14-74
Purpose/Sample
Design
Results
Strengths/Limitat
(Method/Instruments)
ions
Purpose:
Nonexperimental
-Baseline knowledge of HCV was low. Strengths:
To assess attitudes (Quantitative) descriptive
Baseline attitudes were favorable to Indicates that onof Hepatitis C
correlation study.
learning about HCV and receiving free site education is an
(HCV) screening
Hepatitis vaccines.
easy way to
and knowledge of A baseline survey was
-Almost all surveyed wanted
increase awareness
high-risk
screening, even if they weren’t going and desire to be
verbally administered to
populations and
to receive treatment.
tested.
assess attitudes towards
assess knowledge HCV screening and sociogain after receiving demographic information. -Post survey results showed the15Limitations:
an education
minute education intervention
Convenience
intervention.
increased understanding about
sample
A 15-minute educational
Sample/Setting:
treatment the most (71% increase in Bias can exist
verbal discussion at a 5th
n = 140 participants grade education level was correct answer). Understanding risk when verbal
5 sites utilized by conducted that explained
factors and the importance of less
administration is
the Wake County, HCV disease, clinical
alcohol intake also increased. All
used versus
NC public health
values were (p < 0.0074 – 0.0001).
written.
importance, prevention,
department.
Impact of HCV
testing, and treatment. This -Participants who refused testing
2 homeless shelters was given by the same
because treatment was not being
education was
serving men and
measured
investigator at all 5 sites to offered scored lower in HCV
women.
knowledge.
immediately after
ensure consistency of
2 Drug and alcohol information taught.
-Younger white males who knew
intervention.
rehabilitation
someone with HCV was associated
Sustainability of
facilities.
with greater knowledge gain.
results is
Post evaluation was
1 Women’s “drop- verbally administered and
questionable.
in” center.
Conclusion:
performed immediately
after the education
-Combining screening strategy with
Johns Hopkins
on-site education can aid in both
intervention.
Evidence
compliance and HCV knowledge
Appraisal
McNemar test was to assess among high-risk populations and be an
Level of Evidence: the correlation between
initial step in improving the high rates
III
of HCV infection in the homeless.
knowledge gain and
Quality: High
acceptance of HCV testing
from pre to post evaluation.
Author Recommendations: In addition to homeless shelters, other community-based primary care clinics
and opioid treatment centers are excellent places to educate at risk populations about HCV.
Implications: The study provides good understanding of HCV attitudes that exist among homeless
individuals and gives a good evidence that providing HCV education regarding treatment, risk, and testing
increases overall HCV understanding and health compliance.
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Source: Nyamathi, A., Kennedy, B., Branson, C. ,Salen, B., Khalilifard, F., Marfisee, M., …Leake, B.
(2013). Impact of nursing intervention on improving HIV, hepatitis knowledge and mental health among
homeless young adults. Community Mental Health Journal, 49(2), 178-184. doi:10.1007/s10597-012-9524-z
Purpose/Sample
Design
Results
Strengths/
(Method/Instruments)
Limitations
Purpose:
-HHP group had
Strengths:
To assess the impact of a Random Control Trial
improved knowledge
Provided data on younger
gains in HBV/HCV.
at-risk populations.
two-group intervention
between a nurse-led
-All participants randomized -Well-being scores
Supports the understanding
Hepatitis Health
in HHP or AM programs
increased in HHP, but not that positive mental health
Promotion (HHP)
after completing a
in AM group.
can associate to being more
program and an Arts
questionnaire regarding
-HHP program had
interested in taking care of
messaging (AM)
higher scores for all
oneself.
demographics.
program to improve
knowledge measures at Identifies predictors of
HIV, hepatitis
Hepatitis C risk for youth
HHP – 3-4, 45-minute group six months.
knowledge and mental sessions regarding Hepatitis -Participants citing that and young adult as being
health conducted over a A & B vaccines, Hepatitis C “they were trying to get similar to older adults.
six -month period in a and (HCV) education.
life together” on mental
“drop-in” shelter.
health surveys scored
Limitations:
higher in knowledge in Sample size was not
Sample/Setting:
AM program had Arts
all measures, except
ethnically diverse
n=156 young adults,
faculty engage in creative
HBV (all p < 0.05).
Results may reflect the
predominantly white
ways to discuss mental
-Decreased drug use
sample size’s comfort with
male, ages 15-25, use of health with a one-hour
noted in HHP group at learning more traditionally.
drugs with the last 6
discussion on HCV.
six months.
Possible that AM would
months, homeless.
have been more effective
Johns Hopkins
Hepatitis B (HBV) and
Conclusion:
with other ethnicities.
Evidence Appraisal
Hepatitis C (HCV)
Level of Evidence: I
questionnaire was used to
-Using a culturally
Quality: Good
test knowledge gained over sensitive interactive,
six months in both groups. flexible, and empathetic
approach for educating
Linear regression modeling homeless at-risk youth
quantitatively compared AM and young adults
increases knowledge and
and HHP knowledge
engagement regarding
measures.
studied health issues.
Author Recommendations:
HHP intervention may work best with a nurse who is experienced in working/engaging with vulnerable, at
risk youth.
Implications: Homeless youth are becoming more likely to be exposed to HBV and HCV due to prevalent
drug use. Understanding how to relate to young adults may be an important factor in delivering education to
this high-risk group.
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Source: Read, P., Lothian, R., Chronister, K., Gilliver, R., Kearley, J., Dore, G. J., & van Beek, I.
(2017). Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug
injecting populations in a targeted primary health care setting, International Journal of Drug Policy, 47,
209-215. doi:10.1016/j.drugpo.2017.05.032
Purpose/Sample
Purpose: To look at
outcomes of DAA
treatment using two
different adherence
support models.
Enhanced and
standard.

Design
(Method/Instruments)

Results

Strengths/Limitations

-30% reported
Strengths:
homelessness.
-44% reported IV drug use “Real-world data” affecting
at least weekly.
DAA treatment for Hepatitis
-25 of the 72 participants C in highly marginalized
Level of support given was elected for the enhanced
populations with a high rate
determined by patient and support. 0% monthly, 13% of injection drug use.
weekly, 16% daily.
nurse, based on the
patient’s social situation,
Sample/Setting:
ability to store medications -6 of 9 participants in
Limitations:
Primary health care safely, and adherence to weekly enhanced
other daily medications. support received SVR12
setting in Sidney,
Small sample size.
testing.
Australia treating IV
-13/16 daily participants
Standard support –
drug users, sex
Outcomes were not
received SVR 12 testing. compared to other tertiary
workers, and at-risk Independent pick up
youth for Hepatitis C, medications, follow-up
settings.
-Univariate
analysis
phone
call
to
confirm
HIV, and sexually
showed that homelessness Government funded the
transmitted diseases. medication start date,
pathology care at week 4, in the last year as the only medications with no limits on
72 patients
factor impacting lost to
commenced for the end of treatment (EOT)
disease stage, injection drug
and SVR (sustained viral follow up and the ability to use, or alcohol use. No
study. 30% of their
obtain SVR 12 data or
participants had been response) 12.
restrictions placed on
delayed SVR testing.
homeless in the last
reinfection treatment.
Enhanced supportyear. 75 % had IV
-The study showed no
drug use 6 months
Weekly phone calls to
correlation between non
prior to being treated. ensure adherence,
Small percentage of observed monthly, weekly SVR or loss to follow up
and injection drug use.
participants were on or daily dispensing of
Conclusion:
medication at the
opioid therapy.
healthcare setting, liaison -Homelessness and greater
with partner organizations social marginalization
Johns Hopkins
Evidence Appraisal delivering meds to patients appear to have the greatest
Level of Evidence: (prison, psychiatric units, impact on completing HCV
or hospital units).
II
treatment through SVR 12
than injection drug use
Quality: High
alone.
Author Recommendations: Specific strategies are needed to increase adherence to post-treatment follow
up and testing, especially among the homeless. More linkage to care and follow-up models for highly
marginalized populations should be explored.
Quasi-experimental
(Observational cohort
study)

Implications: Enhanced support models as discussed in this study are opportunities for nursing to provide
more support to these communities to ensure treatment adherence.
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Source: Sena, A. C., Willis, S. J., Hilton, A., Anderson, A., Wohl, D. A., Hurt, C. B., & Muir, A. J.
(2016). Efforts at the frontlines: Implementing a hepatitis C testing and linkage-to-care program at the
local public health level. Public Health Reports, 131, 57-64. doi:10.1177/00333549161310S210
Purpose/Sample
Design
Results
Strengths/
(Method/Instruments)
Limitations
Purpose:
Non-experimental
-Linkage to care was most
Strengths:
To increase testing
challenging for uninsured.
-Large sample size
for HCV infection -HCV testing was performed (71%)
by offering HCV
along with testing for HIV
-On-site clinics at homeless Limitations:
testing at established and STDs by clinical or
shelter and other testing sites - Testing was funded by
public health grants
sites already doing health educators.
were instituted.
testing for HIV and -Risk factor information was -12% (241) had chronic HCV specifically focused at
STDs.
collected
-2.5% were co-infected with decreasing HCV
infection.
-Rapid anti-HCV tests were HIV.
Sample/Setting:
done at locations where it
-Highest percentage of HCV -Gift card given
could be hard to otherwise chronic infection was among -Low external validity.
-Not transferrable to all
2,004 anti-HCV tests connect with patient to give the homeless (22.6%)
US public health
were performed on results.
-81.7% received HCV
adults from STD
-Pretest/posttest counseling results/posttest counseling. departments.
clinic, community was done.
68% referred to HCV care. - Treatment completion
and sustained viral
testing sites,
- Linkage to care for HCV 91.8% attended first
response (SVR) was not
homeless clinic,
infection was provided by a appointment.
county jail in
health educator. Reviewed -50% of birth dates of 1945- studied.
Durham County, NC medical/drug history, drug- 1965 had anti-HCV+
reduction counseling,
Conclusion:
Johns Hopkins
scheduled appointments.
Coordination of care with
Evidence Appraisal -Prevalence of Hepatitis C by appointment reminders
testing site was analyzed.
increases compliance.
Level of Evidence: -Referred to liver specialist Having complete contact
III
or infectious disease
information decreases loss to
provider.
follow-up.
Quality: Good
Transportation barriers are
alleviated when testing is
done on-site.
Author Recommendations: Provide HCV testing at existing HIV/STD testing sites to provide HCV
awareness and linkage to a provider’s network for care.
Implications: Instituting a system of coordinated care can significantly impact HCV awareness, testing,
and treatment.
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Source: Williams, B. E., Nelons, D., Seaman, A., Witkowska, M., Ronan, W., Wheelock, H., . . . Garcia,
J. (2019). Life projects: The transformative potential of direct-acting antiviral treatment for hepatitis C
among people who inject drugs. International Journal of Drug Policy, 72, 138-145.
doi:10.1016/j.drugpo.2019.03.015
Purpose/Sample
Design
Results
Strengths/Limitations
(Method/Instruments)
Purpose:
Strengths:
To look for emergent Qualitative study
-Social incentives have a
themes that motivated
positive effect on
Identifies the social
people who inject
Interviews (Life project
completing HCV treatment. incentives for PWID to
drugs (PWID) to
analysis) were conducted
cure their HCV infection.
complete direct-acting on 27 patients
-Both groups viewed HCV
antiviral (DAA)
(approximately half from treatment as an opportunity Identifies the strength of
treatment for HCV
OAT, half from NSP) that to shape how they viewed interviewing patients to
infection.
were at week 10 or 12 of their health, relationships, understand and support
HCV treatment.
and reflect on their drug
their motivations for
use.
better health.
Sample/Setting:
Motivations for seeking
n=27
and completing HCV
-HCV treatment was
Two groups receiving treatment was asked to all viewed as an opportunity to
care from a healthcare participants.
rid the stigma associated
for the homeless
Interviewers specifically with being a drug user and Limitations:
clinics in Portland,
wanted to know how
obtain stable housing,
OR
the individual’s
employment, and healthy Did not discuss SVR 12.
1-Receiving opioid
socioeconomic
living.
antagonist therapy
background, social
Small sample size.
(OAT)
networks, prior medical
Conclusion:
2-partakes in a needle care, history of drug use,
Doesn’t include data for
and syringe exchange stigma surrounding HCV, Understanding personal
themes associated with
program (NSP).
and experience with DAA motivations for completing “not willing to do
treatment affected their
treatment can help
treatment”.
Johns Hopkins
ability to complete
empower PWID to remain
Evidence Appraisal treatment.
virus free regardless of
Level of Evidence:
current or future drug use.
III
Data was collected, coded,
Quality: High
and group into themes
through group discussion
by interviewers.
Author Recommendations: The motivation to complete treatment exists among PWID. However,
simplified universal access to HCV treatment needs to exist also to maximize the benefit of curing HCV
infection in this population.
Implications: Increasing HCV treatment uptake by PWID could have significant effects on disease
burden. Understanding why PWID engage in HCV treatment could be used to develop programs that
encourage more to partake in treatment.

